FDA Accepts Turnstone Biologics' IND for Immunotherapy Targeting HPV Positive Cancers

Turnstone Biologics  announced on 5/16/18 it has received U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug Application (IND) for MG1-HPV for the treatment of patients with human papillomavirus (HPV) positive solid tumors.